rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Lori Lyons-Williams

Director

Company insider

Files Form 4 as: Director, Contineum Therapeutics; Director, RAPT Therapeutics; Director, Five Prime Therapeutics; Chief Commercial Officer, Dermira.

Every Form 4 they filed

In numbers

Trades disclosed
49
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
4
Companies where not an officer
3
First trade
9 Jan 2017
Last trade
26 Jun 2026
Last filed
26 Jun 2026

Companies traded

Where they are an officer
DermiraOfficer · last 20 Feb 20200 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
CTNM Contineum TherapeuticsDirector · Biotechnology · last 26 Jun 20260 buys · 0 sells
RAPT TherapeuticsDirector · Biotechnology · last 3 Mar 20260 buys · 0 sells
Five Prime TherapeuticsDirector · last 16 Apr 20210 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
26 Jun 2026filed 26 Jun 2026CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,000 at $0.00filing
26 Jun 2026filed 26 Jun 2026CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,000 at $0.00filing
3 Mar 2026filed 5 Mar 2026RAPT TherapeuticsBiotechnologySEC FORM 4 Code U—4,956filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—2,813filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—1,063filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivativeSEC FORM 4 Code D—2,813filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivativeSEC FORM 4 Code D—1,063filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivativeSEC FORM 4 Code D—1,618filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivativeSEC FORM 4 Code D—4,561filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivativeSEC FORM 4 Code D—32,229filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—1,618filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—4,561filing
3 Mar 2026filed 5 Mar 2026RAPT Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—32,229filing
3 Mar 2026filed 5 Mar 2026RAPT TherapeuticsSEC FORM 4 Code U—4,956filing
30 Jan 2026filed 2 Feb 2026RAPT TherapeuticsBiotechnologySEC FORM 4 Code A—4,956 at $0.00filing
30 Jan 2026filed 2 Feb 2026RAPT TherapeuticsSEC FORM 4 Code A—4,956 at $0.00filing
26 Jun 2025filed 26 Jun 2025CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—14,750 at $0.00filing
29 May 2025filed 2 Jun 2025RAPT Therapeuticsoption or derivativeSEC FORM 4 Code A—257,832 at $0.00filing
24 May 2024filed 29 May 2024CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—29,500 at $0.00filing
22 May 2024filed 23 May 2024RAPT Therapeuticsoption or derivativeSEC FORM 4 Code A—36,490 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Nobody else traded the same names lately.